TY - JOUR AU - Lee, T. AU - Emanuel, E. PY - 2008 DA - 2008// TI - Tier 4 drugs and the fraying of the social compact JO - NEJM VL - 359 UR - https://doi.org/10.1056/NEJMp0804261 DO - 10.1056/NEJMp0804261 ID - Lee2008 ER - TY - JOUR AU - Wettermark, B. AU - Godman, B. AU - Andersson, K. AU - Gustafsson, L. L. AU - Haycox, A. AU - Bertele, V. PY - 2008 DA - 2008// TI - Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe JO - Pharmacoeconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826070-00001 DO - 10.2165/00019053-200826070-00001 ID - Wettermark2008 ER - TY - JOUR AU - Garattini, L. AU - Motterlini, N. AU - Cornago, D. PY - 2008 DA - 2008// TI - Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries JO - Health Policy VL - 85 UR - https://doi.org/10.1016/j.healthpol.2007.08.005 DO - 10.1016/j.healthpol.2007.08.005 ID - Garattini2008 ER - TY - JOUR AU - Clement, F. AU - Harris, A. AU - Li, J. J. AU - Yong, K. AU - Lee, K. AU - Manns, B. J. PY - 2009 DA - 2009// TI - Using effectiveness and cost-effectiveness to make drug coverage decisions - a comparison of Britain, Australia and Canada JO - JAMA VL - 302 UR - https://doi.org/10.1001/jama.2009.1409 DO - 10.1001/jama.2009.1409 ID - Clement2009 ER - TY - JOUR AU - McCabe, C. AU - Bergmann, L. AU - Bosanquet, N. AU - Ellis, M. AU - Enzmann, H. AU - von Euler, M. AU - Jönsson, B. AU - Kallem, K. -. J. AU - Newling, D. AU - Nussler, V. AU - Paschen, B. AU - de Wilde, R. AU - Wilking, N. AU - Teale, C. AU - Zwierzina, H. PY - 2009 DA - 2009// TI - Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective JO - Annals of Oncology VL - 20 UR - https://doi.org/10.1093/annonc/mdn603 DO - 10.1093/annonc/mdn603 ID - McCabe2009 ER - TY - JOUR AU - Garattini, S. AU - Bertele, V. AU - Godman, B. AU - Haycox, A. AU - Wettermark, B. AU - Gustafsson, L. PY - 2008 DA - 2008// TI - Enhancing the rational use of new medicines across European healthcare systems - A Position Paper JO - Eur Jn Clinical Pharmacology VL - 64 UR - https://doi.org/10.1007/s00228-008-0537-z DO - 10.1007/s00228-008-0537-z ID - Garattini2008 ER - TY - JOUR AU - Cook, J. AU - Vernon, J. AU - Mannin, R. PY - 2008 DA - 2008// TI - Pharmaceutical risk-sharing agreements JO - Pharmacoeconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826070-00002 DO - 10.2165/00019053-200826070-00002 ID - Cook2008 ER - TY - JOUR AU - Godman, B. AU - Wettermark, B. AU - Hoffman, M. AU - Andersson, K. AU - Haycox, A. AU - Gustafsson, L. L. PY - 2009 DA - 2009// TI - Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance JO - Expert Rev Pharmacoeconomics Outcomes Res VL - 9 UR - https://doi.org/10.1586/14737167.9.1.65 DO - 10.1586/14737167.9.1.65 ID - Godman2009 ER - TY - CHAP AU - Walker, A. AU - Booth, C. AU - Brown, A. AU - Paterson, K. PY - 2009 DA - 2009// BT - How much good do new medicines do? Basic & Clin Pharm & Toxicology ID - Walker2009 ER - TY - JOUR AU - McCabe, C. AU - Stafinski, T. AU - Edlin, R. AU - Menon, D. PY - 2010 DA - 2010// TI - Access with evidence development schemes - a framework for description and evaluation JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11530850-000000000-00000 DO - 10.2165/11530850-000000000-00000 ID - McCabe2010 ER - TY - JOUR AU - Godman, B. AU - Bucsics, A. AU - Burkhardt, T. AU - Haycox, A. AU - Seyfried, H. AU - Weininger, P. PY - 2008 DA - 2008// TI - Insight into recent reforms and initiatives in Austria; implications for key stakeholders JO - Expert Rev. Pharmacoeconomcis Outcomes Res VL - 8 UR - https://doi.org/10.1586/14737167.8.4.357 DO - 10.1586/14737167.8.4.357 ID - Godman2008 ER - TY - JOUR AU - Godman, B. AU - Haycox, A. AU - Schwabe, U. AU - Joppi, R. AU - Garattini, S. PY - 2008 DA - 2008// TI - Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies JO - PharmacoEconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826020-00001 DO - 10.2165/00019053-200826020-00001 ID - Godman2008 ER - TY - JOUR AU - Sermet, C. AU - Andrieu, V. AU - Godman, B. AU - Van Ganse, E. AU - Haycox, A. AU - Reynier, J. P. PY - 2010 DA - 2010// TI - Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France JO - Applied Health Economics and Health Policy VL - 8 UR - https://doi.org/10.1007/BF03256162 DO - 10.1007/BF03256162 ID - Sermet2010 ER - TY - JOUR AU - Seeley, E. AU - Kanavos, P. PY - 2008 DA - 2008// TI - Generic medicines from a societal perspective: Savings for healthcare systems? JO - Eurohealth VL - 14 ID - Seeley2008 ER - TY - JOUR AU - Godman, B. AU - Schwabe, U. AU - Selke, G. AU - Wettermark, B. PY - 2009 DA - 2009// TI - Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of Proton Pump Inhibitors and lipid-lowering drugs JO - Pharmacoeconomics VL - 27 UR - https://doi.org/10.2165/00019053-200927050-00010 DO - 10.2165/00019053-200927050-00010 ID - Godman2009 ER - TY - JOUR AU - Godman, B. AU - Burkhardt, T. AU - Bucsics, A. AU - Wettermark, B. AU - Weininger, P. PY - 2009 DA - 2009// TI - Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future JO - Expert Rev Pharmacoeconomcis and Outcomes Research VL - 9 UR - https://doi.org/10.1586/erp.09.43 DO - 10.1586/erp.09.43 ID - Godman2009 ER - TY - STD TI - AIFA - Italian Medicines Agency: Working Group on Innovative Drugs. Criteria for Ranking Therapeutic Innovation of New Drugs and Elements for Supplementing the Dossier for Admission to the Reimbursement System (document approved by the AIFACTS on July 10, 2007) (accessed 3 March 2010), [http://www.agenziafarmaco.it/allegati/integral_document.pdf] UR - http://www.agenziafarmaco.it/allegati/integral_document.pdf ID - ref17 ER - TY - CHAP PY - 2007 DA - 2007// TI - The pharmaceutical price regulation system: an OFT study BT - Annexe K: International survey of pharmaceutical pricing and reimbursement schemes PB - The Office of Fair Trading CY - London ID - ref18 ER - TY - CHAP PY - 2007 DA - 2007// TI - Innovative approaches to pricing BT - IMS Pharma Pricing & Reimbursement ID - ref19 ER - TY - JOUR AU - Briggs, A. AU - Ritchie, K. AU - Fenwick, E. AU - Chalikidou, K. AU - Littlejohns, P. PY - 2010 DA - 2010// TI - Access with evidence development in the UK - past experience, current initiatives and future potential JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11531410-000000000-00000 DO - 10.2165/11531410-000000000-00000 ID - Briggs2010 ER - TY - CHAP AU - Hirschler, B. PY - 2008 DA - 2008// BT - Roche plans to address cost of Avastin in Europe ID - Hirschler2008 ER - TY - JOUR AU - de Pourville, G. PY - 2006 DA - 2006// TI - Risk-sharing arrangements for innovative drugs. A new solution to old problems JO - Eur J Health Econ VL - 7 UR - https://doi.org/10.1007/s10198-006-0386-6 DO - 10.1007/s10198-006-0386-6 ID - de Pourville2006 ER - TY - CHAP PY - 2008 DA - 2008// BT - Cancer drugs costing £50 billion will crush the NHS, says expert ID - ref23 ER - TY - JOUR AU - Jirillo, A. AU - Vascon, F. AU - Giacobbo, M. PY - 2008 DA - 2008// TI - Bevacizumab in advanced cancer, too much or too little? JO - Annals of Oncology VL - 19 UR - https://doi.org/10.1093/annonc/mdn564 DO - 10.1093/annonc/mdn564 ID - Jirillo2008 ER - TY - JOUR AU - Breckenridge, A. AU - Walley, T. PY - 2008 DA - 2008// TI - Risk sharing and payment by results JO - Clin Pharmacol and Therapeutics VL - 83 UR - https://doi.org/10.1038/clpt.2008.15 DO - 10.1038/clpt.2008.15 ID - Breckenridge2008 ER - TY - JOUR AU - Møldrup, C. PY - 2005 DA - 2005// TI - No cure, no pay JO - BMJ VL - 330 UR - https://doi.org/10.1136/bmj.330.7502.1262 DO - 10.1136/bmj.330.7502.1262 ID - Møldrup2005 ER - TY - JOUR AU - Chapman, S. AU - Reeve, E. AU - Rajaratnam, G. AU - Neary, R. PY - 2003 DA - 2003// TI - Setting up an outcomes guarantee for pharmaceuticals: New approach to risk sharing in primary care JO - BMJ VL - 326 UR - https://doi.org/10.1136/bmj.326.7391.707 DO - 10.1136/bmj.326.7391.707 ID - Chapman2003 ER - TY - JOUR AU - Carapinha, C. PY - 2008 DA - 2008// TI - Setting the stage for risk-sharing agreements: International experiences and outcomes-based reimbursement JO - SA Fam Pract VL - 50 ID - Carapinha2008 ER - TY - STD TI - NICE draft recommendation on the use of drugs for renal cancer. 2009/009. [Accessed 3 March 2010], [http://www.nice.org.uk/media/420/AD/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf] UR - http://www.nice.org.uk/media/420/AD/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf ID - ref29 ER - TY - CHAP PY - 2009 DA - 2009// BT - Final NICE Kidney Cancer Guidance Recommends sunitinib ID - ref30 ER - TY - CHAP PY - 2009 DA - 2009// BT - Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy ID - ref31 ER - TY - CHAP PY - 2009 DA - 2009// BT - UK's NICE approves lenalidomide in relapsed multiple myeloma ID - ref32 ER - TY - JOUR AU - Robertson, J. AU - Walkom, E. AU - Henry, D. PY - 2009 DA - 2009// TI - Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme JO - Aust Health Rev VL - 33 UR - https://doi.org/10.1071/AH090192 DO - 10.1071/AH090192 ID - Robertson2009 ER - TY - JOUR AU - Stafinski, T. AU - McCabe, C. AU - Menon, D. PY - 2010 DA - 2010// TI - Funding the unfundable - mechanisms for managing uncertainty in decisions on the introduction o new and innovative technologies into healthcare systems JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11530820-000000000-00000 DO - 10.2165/11530820-000000000-00000 ID - Stafinski2010 ER - TY - CHAP AU - Taylor, L. PY - 2008 DA - 2008// BT - New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution ID - Taylor2008 ER - TY - JOUR AU - Towse, A. AU - Garrison, L. PY - 2010 DA - 2010// TI - Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11314080-000000000-00000 DO - 10.2165/11314080-000000000-00000 ID - Towse2010 ER - TY - JOUR AU - Jack, A. PY - 2008 DA - 2008// TI - Balancing Big Pharma's books JO - BMJ VL - 336 UR - https://doi.org/10.1136/bmj.39491.469005.94 DO - 10.1136/bmj.39491.469005.94 ID - Jack2008 ER - TY - JOUR AU - Barrett, A. AU - Riques, T. AU - Small, M. AU - Smith, R. PY - 2006 DA - 2006// TI - How much will Herceptin really cost? JO - BMJ VL - 333 UR - https://doi.org/10.1136/bmj.39008.624051.BE DO - 10.1136/bmj.39008.624051.BE ID - Barrett2006 ER - TY - JOUR AU - Mohr, P. AU - Tunis, S. PY - 2010 DA - 2010// TI - Access with evidence development - the US experience JO - Pharmaceoeconomics VL - 28 UR - https://doi.org/10.2165/11531050-000000000-00000 DO - 10.2165/11531050-000000000-00000 ID - Mohr2010 ER - TY - STD TI - Leader. Looking beyond the headlines. The Lancet Oncology. 2007, 8: 561-10.1016/S1470-2045(07)70178-X. ID - ref40 ER - TY - JOUR AU - Williamson, S. PY - 2010 DA - 2010// TI - Patient access schemes for high-cost cancer medicines JO - Lancet VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70402-4 DO - 10.1016/S1470-2045(09)70402-4 ID - Williamson2010 ER - TY - BOOK AU - Sturm, H. AU - Austvoll-Dahlgren, A. AU - Aaserud, M. PY - 2007 DA - 2007// TI - Pharmaceutical policies: effects of financial incentives for prescribers (Review) ID - Sturm2007 ER - TY - CHAP AU - de Swaef, A. AU - Antonissen, Y. PY - 2007 DA - 2007// BT - Pharmaceutical Pricing and Reimbursement Information, Belgium ID - de Swaef2007 ER - TY - CHAP AU - Espín, J. AU - Rovira, J. PY - 2007 DA - 2007// TI - Analysis of differences and commonalities in pricing and reimbursement systems in Europe BT - A study funded by DG Enterprise and Industry of the European Commission ID - Espín2007 ER - TY - CHAP AU - Pudersell, K. AU - Vetka, A. AU - Rootslane, L. AU - Mari, M. a. t. h. i. e. s. e. n. PY - 2007 DA - 2007// BT - Pharmaceutical Pricing and Reimbursement Information, ESTONIA ID - Pudersell2007 ER - TY - STD TI - Health Systems in Transition. Estonia Health. 2008, 10 (1): (Accessed 3 March 2010), [http://www.hpm.org/Downloads/reports/HiT_reports/Hit_Estonia_2008.pdf] UR - http://www.hpm.org/Downloads/reports/HiT_reports/Hit_Estonia_2008.pdf ID - ref46 ER - TY - CHAP AU - Grandfils, N. PY - 2008 DA - 2008// TI - Drug price setting and regulation in France BT - Working paper (DT number 16) ID - Grandfils2008 ER - TY - CHAP PY - 2008 DA - 2008// BT - Healthcare Products Pricing Committee Annual Report ID - ref48 ER - TY - STD TI - European Legal Developments Bulletin: 2007, 19 (2): 17-19. spring ID - ref49 ER - TY - CHAP AU - Kovács, T. AU - Rózsa, P. AU - Szigeti, S. PY - 2007 DA - 2007// BT - Pharmaceutical Pricing and Reimbursement Information, HUNGARY ID - Kovács2007 ER - TY - CHAP AU - Folino Gallo, P. AU - Deambrosis, P. PY - 2008 DA - 2008// BT - Pharmaceutical risk-sharing and conditional reimbursement in Italy ID - Folino Gallo2008 ER - TY - CHAP AU - Barros, P. AU - de Almeida Simões, J. PY - 2007 DA - 2007// BT - Health Systems in Transition ID - Barros2007 ER - TY - CHAP AU - Teixeira, I. AU - Vieira, I. PY - 2008 DA - 2008// BT - Pharmaceutical Pricing Reimbursement Information, Portugal ID - Teixeira2008 ER - TY - STD TI - Cetuximab for first line treatment of metastatic colorectal cancer (MCRC). 2009, [Accessed 3 March 2010], [http://www.nice.org.uk/nicemedia/pdf/ColorectalCancerCetuxamibACD2ManPAS.pdf] UR - http://www.nice.org.uk/nicemedia/pdf/ColorectalCancerCetuxamibACD2ManPAS.pdf ID - ref54 ER - TY - STD TI - NICE draft recommendation on the use of drugs for renal cancer. 2009/009. [Accessed 29 July 09], [http://www.nice.org.uk/media/420/AD/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf] UR - http://www.nice.org.uk/media/420/AD/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf ID - ref55 ER - TY - CHAP PY - 2009 DA - 2009// BT - Final NICE Kidney Cancer Guidance Recommends sunitinib ID - ref56 ER - TY - CHAP PY - 2010 DA - 2010// BT - Scottish Medicines Consortium - cetuximab, 100 mg/20 ml and 500 mg/100 ml solution for intravenous infusion ID - ref57 ER - TY - CHAP PY - 2008 DA - 2008// TI - Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) For Wet AMD in UK BT - Scrip News ID - ref58 ER - TY - STD TI - NICE: Costing statement: Ustekinumab for the treatment of adults with moderate to severe psoriasis. [Accessed 3 March 2010], [http://www.nice.org.uk/nicemedia/pdf/TA180UstekinumabForTheTreatmentOfPsoriasisCostingStatement.pdf] UR - http://www.nice.org.uk/nicemedia/pdf/TA180UstekinumabForTheTreatmentOfPsoriasisCostingStatement.pdf ID - ref59 ER - TY - CHAP PY - 2010 DA - 2010// BT - Scottish Medicines Consortium - ustekinumab 45 mg solution for injection ID - ref60 ER - TY - CHAP AU - Herper, M. PY - 2006 DA - 2006// BT - Top of The Cancer Market? ID - Herper2006 ER - TY - CHAP AU - Pollack, A. PY - 2006 DA - 2006// BT - Genentech Caps Cost of Cancer Drug for Some Patients ID - Pollack2006 ER - TY - CHAP PY - 2008 DA - 2008// BT - Injectable claim edit (maximum dosage drug policy) ID - ref63 ER - TY - CHAP PY - 2008 DA - 2008// BT - Generic Biotech Products: Are the Floodgates Open? At Whose Expense?, Biotech Business ID - ref64 ER - TY - STD TI - Amgen: Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients. (Accessed 3 March 2010), [http://findarticles.com/p/articles/mi_m0EIN/is_2006_Sept_27/ai_n16836635/] UR - http://findarticles.com/p/articles/mi_m0EIN/is_2006_Sept_27/ai_n16836635/ ID - ref65 ER - TY - STD TI - Sanofi-Aventis: Sculptra™ Patient Access Program. [Accessed 3 March 2010], [http://www.pparx.org/resources/2008-05-19.SanofiAventis.Sculptra_Patient_Access_Program.3008.pdf] UR - http://www.pparx.org/resources/2008-05-19.SanofiAventis.Sculptra_Patient_Access_Program.3008.pdf ID - ref66 ER - TY - STD TI - Gilead: Need Help Paying for TRUVADA?. [Accessed 3 March 2010], [http://www.truvada.com/pat400_paying_for_your_hiv_meds.aspx] UR - http://www.truvada.com/pat400_paying_for_your_hiv_meds.aspx ID - ref67 ER - TY - CHAP AU - Hart, C. a. r. l. y. PY - 2009 DA - 2009// BT - Free Prescription Drugs to Unemployed Courtesy of Pfizer, Inc ID - Hart2009 ER - TY - STD TI - Anderson P: Clozapine comes with money-back offer. (accessed 3 March 2010), [http://www.mentalhealth.com/mag1/p51-cloz.html] UR - http://www.mentalhealth.com/mag1/p51-cloz.html ID - ref69 ER - TY - STD TI - Fuschillo C, Ascoli F, Franzese G, Campana F, Cello C, Galdi M, La Pia S, Cetrangolo C: Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. Arch Gerontol Geriatr Suppl. 2004, 187-94. 10.1016/j.archger.2004.04.026. 9 ID - ref70 ER - TY - JOUR AU - Bellelli, G. AU - Lucchi, E. AU - Minicuci, N. AU - Rozzini, L. AU - Bianchetti, A. AU - Padovani, A. AU - Trabucchi, M. PY - 2005 DA - 2005// TI - Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study JO - Aging Clin Exp Res VL - 17 UR - https://doi.org/10.1007/BF03337721 DO - 10.1007/BF03337721 ID - Bellelli2005 ER - TY - STD TI - Anon NICE: Final appraisal determination bortezomib monotherapy for relapsed multiple myeloma. (accessed 3 March 2010), [http://www.nice.org.uk/nicemedia/pdf/FAD.pdf] UR - http://www.nice.org.uk/nicemedia/pdf/FAD.pdf ID - ref72 ER - TY - JOUR AU - Garber, A. AU - McCellan, M. PY - 2007 DA - 2007// TI - Satisfaction guaranteed - 'Payment by results' for biologic agents JO - NEJM VL - 357 UR - https://doi.org/10.1056/NEJMp078204 DO - 10.1056/NEJMp078204 ID - Garber2007 ER - TY - JOUR AU - Chapman, S. AU - Reeve, E. AU - Rajaratnam, G. AU - Neary, R. PY - 2004 DA - 2004// TI - Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care JO - Br J cardiol VL - 11 ID - Chapman2004 ER - TY - CHAP PY - 2007 DA - 2007// BT - The Pharmaceutical Price regulation System - An OFT study ID - ref75 ER - TY - JOUR AU - Boggild, M. AU - Palace, J. AU - Barton, P. AU - Ben-Shlomo, Y. AU - Bregenezer, T. AU - Dobson, C. AU - Gray, R. PY - 2009 DA - 2009// TI - Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator JO - BMJ VL - 339 UR - https://doi.org/10.1136/bmj.b4677 DO - 10.1136/bmj.b4677 ID - Boggild2009 ER - TY - CHAP AU - Haan, G. AU - Rutten, F. PY - 1989 DA - 1989// BT - No cure, no pay: an acceptable way of financing fertility treatments? Health Policy ID - Haan1989 ER - TY - JOUR AU - Cramer, J. A. AU - Benedict, A. AU - Muszabek, N. AU - Keskinaslan, A. AU - Khan, Z. PY - 2008 DA - 2008// TI - The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review JO - Int J Clin Pract VL - 62 UR - https://doi.org/10.1111/j.1742-1241.2007.01630.x DO - 10.1111/j.1742-1241.2007.01630.x ID - Cramer2008 ER - TY - JOUR AU - Wettermark, B. AU - Godman, B. AU - Jacobsson, B. AU - Haaijer-Ruskamp, F. PY - 2009 DA - 2009// TI - Soft Regulations in Pharmaceutical Policymaking: An Overview of Current Approaches and their Consequences JO - Appl Econ Health Policy VL - 7 UR - https://doi.org/10.1007/BF03256137 DO - 10.1007/BF03256137 ID - Wettermark2009 ER - TY - JOUR AU - Hyde, R. PY - 2007 DA - 2007// TI - Doctors to pay for patients' medicine in Germany JO - Lancet VL - 370 UR - https://doi.org/10.1016/S0140-6736(07)61494-9 DO - 10.1016/S0140-6736(07)61494-9 ID - Hyde2007 ER - TY - STD TI - Yack D: Adherence to long-term therapies - Evidence for action. WHO 2003 - WHO/MNC/03.01. (Accessed 3 March 2010), [http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf] UR - http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf ID - ref81 ER - TY - CHAP AU - Horne, R. AU - Weinman, J. AU - Barber, N. PY - 2005 DA - 2005// TI - Concordance, adherence and compliance in medicine taking BT - NCCSDO ID - Horne2005 ER - TY - CHAP AU - Perreault, S. AU - Dragomir, A. AU - Blais, L. AU - Berrard, A. AU - Lalonde, L. AU - White, M. AU - Pilon, D. PY - 2009 DA - 2009// TI - Impact of better adherence to statin agents in the primary prevention of coronary artery disease BT - Eur J Clin Pharmacol ID - Perreault2009 ER - TY - JOUR AU - Garattini, S. AU - Bertele', V. PY - 2007 DA - 2007// TI - How can we regulate medicines better JO - BMJ VL - 335 UR - https://doi.org/10.1136/bmj.39281.615706.94 DO - 10.1136/bmj.39281.615706.94 ID - Garattini2007 ER - TY - JOUR AU - Apolone, G. AU - Joppi, R. AU - Bertele, V. AU - Garattini, S. PY - 2005 DA - 2005// TI - Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures JO - British Journal of Cancer VL - 93 UR - https://doi.org/10.1038/sj.bjc.6602750 DO - 10.1038/sj.bjc.6602750 ID - Apolone2005 ER - TY - CHAP AU - Joppi, R. AU - Dematte, L. AU - Menti, A. M. AU - Pase, D. AU - Poggiani, C. AU - Mezzalira, L. PY - 2009 DA - 2009// TI - The Italian Horizon Scanning project BT - Eur J Clin Pharmacol ID - Joppi2009 ER - TY - JOUR AU - Claxton, K. AU - Briggs, A. AU - Buxton, M. AU - Culyer, A. AU - McCabe, C. AU - Walke, S. AU - Sculpher, M. PY - 2008 DA - 2008// TI - Value based pricing for NHS drugs: an opportunity not to be missed? JO - BMJ VL - 336 UR - https://doi.org/10.1136/bmj.39434.500185.25 DO - 10.1136/bmj.39434.500185.25 ID - Claxton2008 ER - TY - JOUR AU - Pegler, S. AU - Underhill, J. PY - 2005 DA - 2005// TI - Evaluating promotional material from industry: an evidence-based approach JO - Pharmaceutical Jn VL - 274 ID - Pegler2005 ER - TY - JOUR AU - Walley, T. PY - 2007 DA - 2007// TI - Fair pricing for medicines in the UK JO - Expert Rev Pharmacoeconomics and Outcomes Res VL - 7 UR - https://doi.org/10.1586/14737167.7.3.207 DO - 10.1586/14737167.7.3.207 ID - Walley2007 ER - TY - JOUR AU - Webb, D. AU - Walker, A. PY - 2007 DA - 2007// TI - Value-based pricing of drugs in the UK JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60648-5 DO - 10.1016/S0140-6736(07)60648-5 ID - Webb2007 ER - TY - CHAP AU - Walley, T. PY - 2004 DA - 2004// BT - Neuropsychotherapeutics in the UK; what has been the impact of NICE? CNS Drugs ID - Walley2004 ER - TY - JOUR AU - Duerden, M. AU - Gogna, N. AU - Godman, B. AU - Eden, K. AU - Mallinson, M. PY - 2004 DA - 2004// TI - Current National Initiatives Policies to control drug costs in Europe: UK perspective JO - J Ambulatory Care Manage VL - 27 UR - https://doi.org/10.1097/00004479-200404000-00009 DO - 10.1097/00004479-200404000-00009 ID - Duerden2004 ER - TY - JOUR AU - Sudlow, S. AU - Counsel, C. PY - 2003 DA - 2003// TI - Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis JO - BMJ VL - 326 UR - https://doi.org/10.1136/bmj.326.7385.388 DO - 10.1136/bmj.326.7385.388 ID - Sudlow2003 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/10/153/prepub UR - http://www.biomedcentral.com/1472-6963/10/153/prepub ID - ref94 ER -